Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)
ID: 358238Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358238

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-26-007.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for collaborative research projects focused on type 1 diabetes, specifically utilizing biosamples and data from established clinical studies. The objective is to advance the understanding of the disease's etiology and pathogenesis, with funding available for studies that aim to explore disease mechanisms, delay onset, and improve prevention strategies. A total of $5.5 million is committed for up to four awards in Fiscal Years 2026 and 2027, with application deadlines beginning on May 26, 2025, and a final submission date of March 9, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DK-26-007.html
    The National Institutes of Health (NIH) has issued a Notice of Funding Opportunity (NOFO) for research projects focused on type 1 diabetes, particularly using biosamples and data from established clinical studies. This funding, under the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), aims to advance understanding of the disease's etiology and pathogenesis through collaborative research. Applicants can request funding to study disease mechanisms, delaying onset, and improving prevention strategies, with a total commitment of $5.5 million available for up to four awards in both Fiscal Year 2026 and 2027. Important application requirements include adherence to specific submission guidelines, registration with relevant agencies, and the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to foster inclusivity in research teams. Projects must use existing clinical data and biosamples approved by NIDDK and comply with NIH data-sharing policies. Eligible applicants include various education institutions, nonprofit organizations, and government entities, and applications will undergo rigorous scientific review to ensure merit. The proposal submission deadlines begin on May 26, 2025, with an expiration date set for March 9, 2026, making it essential for interested parties to prepare early.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for a cooperative agreement aimed at advancing research on Type 1 Diabetic nephropathy (T1D). This initiative seeks applications from Recruitment Sites (RS) to enroll adult and pediatric patients with T1D, particularly those at high risk for diabetic nephropathy, into a longitudinal cohort study, which will include protocol-based kidney biopsies. The research will leverage existing resources from the Kidney Precision Medicine Project (KPMP) to create a Kidney Tissue Atlas, identify disease subgroups, and explore novel therapeutic targets. The estimated total program funding for this opportunity is $1.3 million, with the NOFO expected to be published in fall 2024 and applications due in late fall 2024. Interested applicants are encouraged to reach out to the NIDDK contacts provided in the announcement for further information.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for investigator-initiated, high-risk multi-center clinical trials through the Notice of Funding Opportunity (NOFO) PA-25-147. This cooperative agreement (U01) aims to support innovative studies that address critical health issues related to diabetes, digestive diseases, and kidney conditions, requiring proposals to be hypothesis-driven and operationally classified as high-risk. The program emphasizes the importance of diverse perspectives in research and mandates that planning activities be completed prior to application submission. Interested applicants should note that the application period opens on January 3, 2025, with a submission deadline of November 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK Centers for Diabetes Translation Research (P30 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Centers for Diabetes Translation Research (CDTR) under the funding opportunity RFA-DK-26-001, aimed at advancing diabetes translational research from clinical settings to community practice. This initiative seeks to foster innovative research that addresses health equity and reduces diabetes-related disparities through multidisciplinary collaborations and core services that enhance productivity and synergy among funded investigators. Eligible applicants include a wide range of institutions, such as higher education institutions, nonprofits, and government entities, with annual budgets capped at $400,000, potentially increasing to $500,000 for specific cores. Applications are due by May 12, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk, multi-center observational studies related to diabetes, digestive, kidney, and associated diseases. This funding opportunity emphasizes hypothesis-driven research that engages diverse populations, particularly underserved communities, and requires a comprehensive study design, community engagement, and a detailed budget. The initiative is crucial for advancing health equity and enhancing participant diversity in clinical research. Interested applicants should note that the submission period opens on January 3, 2025, with a closing date of November 5, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk observational studies related to diabetes, digestive, kidney, and metabolic diseases. Applicants must complete all planning activities prior to submission, as these cannot be included in the U01 application, and a Plan for Enhancing Diverse Perspectives (PEDP) is mandatory for consideration. This funding opportunity is crucial for advancing clinical research and addressing health disparities, particularly by encouraging collaboration with underrepresented communities. Interested applicants should note that the application deadline is February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity titled "NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)." This initiative aims to support high-risk, investigator-initiated, multi-center clinical studies by facilitating early peer review and the development of essential operational documents necessary for conducting the proposed studies. The program emphasizes the importance of addressing diseases affecting underrepresented populations and requires applicants to include a Plan for Enhancing Diverse Perspectives (PEDP) in their submissions. The maximum award amount is $225,000 per year for up to two years, with applications opening on May 9, 2025, and a submission deadline of June 10, 2027. Interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Impact, Interdisciplinary Science in NIDDK Research Areas" (PAR-25-277) aimed at supporting innovative research that addresses critical knowledge gaps in diabetes, digestive, and kidney diseases. This grant program encourages interdisciplinary approaches to foster discovery-based science and develop transformative technologies that can significantly impact the broader scientific community. Eligible applicants include a wide range of organizations, such as higher education institutions and nonprofits, with proposals accepted for projects lasting up to five years. Interested parties should ensure compliance with application guidelines and submit their proposals by the deadline of October 15, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-277.html.
    Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), has announced a funding opportunity for small R01 grants aimed at supporting clinical trials that address diseases within its mission. This initiative encourages pilot and feasibility studies in human subjects to gather preliminary and feasibility data necessary for larger clinical trials focused on the prevention and treatment of diabetes and other related conditions. With an anticipated budget of $1 million for fiscal year 2025, NIDDK plans to fund up to three awards, each with a maximum direct cost of $200,000 annually over a three-year project period. Interested applicants must submit their proposals electronically through Grants.gov by May 7, 2026, and are encouraged to include a "Plan for Enhancing Diverse Perspectives" to promote inclusivity in their research efforts. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)." This initiative aims to promote exploratory research into the biological mechanisms by which incretin mimetics, particularly GLP-1 and dual GLP-1/GIP-1 receptor agonists, influence cancer risk, with a focus on understanding their effects beyond diabetes treatment. The funding, which amounts to a maximum of $275,000 over two years, is intended to attract diverse researchers and institutions to fill significant gaps in current cancer biology research. Interested applicants should note that the application submission period begins on January 16, 2025, and can find further details and guidelines at the NIH grants website or by contacting NIH Grants Information at grantsinfo@nih.gov.
    NIDDK Central Repository Non-renewable Sample Access (X01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "NIDDK Central Repository Non-renewable Sample Access," aimed at facilitating access to valuable biological samples for research in health-related fields, particularly diabetes, kidney, and digestive diseases. Eligible applicants, including various educational institutions and organizations, can apply for access to non-renewable samples and associated data from significant clinical studies, with the requirement to submit a report from the NIDDK Central Repository documenting sample availability. This initiative promotes equitable distribution of samples and collaboration among researchers to enhance research outcomes, with no funds awarded; instead, access approvals are based on the scientific merit of applications and sample availability. Interested parties should note that the application deadline is June 26, 2025, and are encouraged to engage with the Repository at least six weeks prior to submission for an assessment. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.